Gemcitabine (Gem) and nab-paclitaxel (NP) ± nivolumab (nivo) ± CD40 agonistic monoclonal antibody APX005M (sotigalimab), in patients (Pts) with untreated metastatic pancreatic adenocarcinoma (mPDAC): Phase (Ph) 2 final results.

Mark H. OHara,Eileen M. OReilly,Robert A. Wolff,Zev A. Wainberg,Andrew H. Ko,Osama E. Rahma,George A. Fisher,Jaclyn P. Lyman,Christopher R. Cabanski,Joyson Joseph Karakunnel,Pier Federico Gherardini,Lacey J. Kitch,Samantha Bucktrout,Elizabeth Christopher,Rosemarie Mick,Richard Chen,Ovidiu C. Trifan,Lisa Salvador,Jill ODonnell-Tormey,Robert H. Vonderheide

Gemcitabine (Gem) and nab-paclitaxel (NP) ± nivolumab (nivo) ± CD40 agonistic monoclonal antibody APX005M (sotigalimab), in patients (Pts) with untreated metastatic pancreatic adenocarcinoma (mPDAC): Phase (Ph) 2 final results.

2021

4019Background: Results from a ph1b trial evaluating gem/NP with CD40 agonistic monoclonal antibody APX005M ± nivo demonstrated promising clinical activity in pts with untreated mPDAC (O’Hara 2021)...

Keywords:

Nivolumab
Medicine
Metastatic Pancreatic Adenocarcinoma
CD40 Agonistic Monoclonal Antibody APX005M
Gemcitabine
in patient
Nab-paclitaxel
Cancer research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations